The qualitative microscopic analysis of the GHRP-6 responsive wounds indicated that the peptide seems to primarily reduce both local hypercellularity associated with the cartilage perichondrium cells and the resulting ECM accumulation (Figures 6(a) and 6(b)). Accordingly, their SEI () appeared largely different () as compared to the placebo samples group (). It is notorious, however, that those GHRP-6 nonresponsive wounds () that evolved to HTS exhibited similar microscopic appearance (not shown) and SEI values as compared to placebo control wounds (Table 3).
The evidence derived from these experiments supports the notion that CD36 is an active and approachable receptor to modulate the healing process. Here we have observed that CD36 occupation by GHRP-6 attenuates wound inflammation, accelerates wound closure, and above all improved wound’s esthetic outcome by impacting ECM proteins accumulation. To our knowledge these findings are unprecedented for GHRP-6 within the context of cutaneous healing.
GHRP mechanism of action. GHRPs are endowed with the ability to bind two different receptors that seem to mediate its cytoprotective and other pharmacological properties (GHS-R1a and CD36). The main biological properties/pharmacological actions of GHRP-6 as cyto- and cardioprotective candidates are summarized as follows: Inotropic: mediated by an elevation of Ca2+ influx via PLC/DAG/PKC, through the voltage-gated calcium channel, triggering Ca2+ release from thapsigargin-sensitive intracellular stores, which translated in a positive inotropic response without a chronotropic effect. Anti-fibrotic: via upregulation of PPARγ, which is followed by a transforming growth factor-beta (TGF-β), CTGF, and platelet-derived growth factor (PDGF) downregulation. Anti-inflammatory: blunts NFκB expression and activation. Cell survival: it involves the phosphatidylinositol 3-kinase/RAC-alpha serine/threonine-protein kinase (PI-3K/AKT1) pathway, as the induction of the hypoxia-inducible factor-1 alpha (HIF-1α). Cardioprotective: as shown, it involves different biological actions that converge to enhance cardiomyocytes survival. Vasodilatory: it seems to involve e-NOS upregulation and endothelin activity reduction. Anabolic: it is mediated by the IGF-1/AKT1 and mTOR pathway activity.

Author Contributions: Conceived and designed the experiments: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, GGN. Analyzed the data: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB. Wrote the first draft of the manuscript: JBA. Contributed to the writing of the manuscript: JBA, AGO, YMM. Agree with manuscript results and conclusions: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, QB, GGN. Jointly developed the structure and arguments for the paper: JBA, AGO, GGN. Made critical revisions and approved final version: QB, GGN. All authors reviewed and approved of the final manuscript.


When you increase the dosage gradually it is also going to ensure you do not experience all (or any) of the noted side effects which are possible with the use of Ipamorelin. And, if you are taking other peptides, supplements, or growth hormones, it is the best way to ensure they are going to acclimate well and work together well, in order for you to realize the greatest results possible when trying to increase muscle mass, and lean muscle tissue, without putting on body fat in the process.
Triamcinolone acetonide (TA) has long been the steroid of choice for the treatment of skin fibrotic disorders, providing the best relief of local symptoms such as scars flattening. Nevertheless, TA is associated with adverse events such as dermal atrophy, telangiectasia, and immunosuppression [4, 5]. Despite the multitude of therapeutic strategies to prevent or reduce keloid and HTS formation, these conditions remain as orphan clinical niches of ultimately effective interventions [6].
Results in Fig. 1.8 of normal young men (left panel) and women (right panel) demonstrate that iv bolus combined GHRP-2 and GHRH at the respective doses of 1 μg/kg GHRH and a subthreshold GH-releasing dose of 0.03 μg/kg GHRP-2 released GH synergistically (Bowers, 1998). From these studies, GHRP is envisioned to act on the hypothalamus to release an unknown factor (U factor) rather than endogenous GHRH which subsequently acts concomitantly with GHRH on the pituitary somatotroph to release GH synergistically. In this study, the important specific finding is that GHRP-2 augments GHRH release even when GHRH is present in excess amounts, and the concomitant GHRP-2 dose of 0.03 μg/kg is a subthreshold GH-releasing amount. Thus, GHRP + GHRH is not releasing GH in this study by augmenting endogenous GHRH release and, furthermore, GHRP+GHRH release in vitro is additive and not synergistic. In addition, from other high-dosage GHRP-2 data, that is, 10 μg/kg sc (not shown), we have postulated that at high doses GHRPs do act on the hypothalamus to release endogenous GHRH because high-dose GHRP-2 (10 μg/kg sc) releases the same large amount of GH released by combined GHRH + GHRP-2 at 1 + 1 μg/kg iv (Bowers, 1998a,b).
CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicing the effect of GHRH).  It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this.It stimulates production of our own growth hormone from the pituitary gland.  

More than a decade ago, CD36 was identified as one of the GHRP-6 receptors [12]. This is a scavenger receptor endowed with multiligand and multifunctional capabilities and is expressed by a broad constellation of mammalian cells [13]. Granulation tissue neovascularization is perhaps the most renowned physiological role of CD36 in wound healing [14]. Serendipitous observations of our laboratory indicated that CD36 mRNA transcript appeared abundantly represented in clinical samples of granulation tissue of either acute (deep burn injuries) or chronic (pressure ulcers) wounds, as in laboratory rat’s controlled full-thickness wounds. This finding incited us to speculate on the effects associated with CD36 agonistic stimulation beyond that of the angiostatic action via thrombospondin binding [15]. Here we provide the first experimental evidence on the favorable impact of the topical administration of GHRP-6, as a candidate to qualitatively improve the healing process.


As an extra note, there are a few things that should be mentioned about increased prolactin and cortisol levels when using certain peptides. My experience is with even high and frequent doses cortisol was raised but nothing to be alarmed about. Also, some peptides are sensitive to foods interfering with the peptides ability to take effect. Therefore, a safe rule of thumb is to not eat 30 minutes before and after dosing to make sure that no foods are facilitating the breakdown of these peptide chains upon subcutaneous or intramuscular injection.
The interim decision was to include in Schedule 4 and in Appendix D Item 5 Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604.
As judged by the PubMed outcomes, the cytoprotective effects of synthetic peptidyl GHRP appear far less studied in noncardiac, parenchymal epithelial organs or multiple organ systems than in the cardiovascular system. However, the results of the reviewed studies are consistent with a broad cytoprotective influence for various organs by reducing inflammation and preventing necrosis and/or apoptosis. The mechanism of GHRP-mediated pharmacological actions is shown in Figure 4.
GHRP-6 is a potent stimulator of natural Growth Hormone release. GHRP-6 is a Hexa-peptide that promotes food intake by stimulating hunger and helps increase energy metabolism. Growth Hormone Releasing Peptides, similar to GHRP-6, are most commonly used for treatment of Growth Hormone (GH) deficiencies, eating disorders, obesity, etc. Research has shown that use of these HGH Peptides increases lean muscle mass, strength, stamina and decreases body fat.
GHRP-6 is a potent stimulator of natural Growth Hormone release. GHRP-6 is a Hexa-peptide that promotes food intake by stimulating hunger and helps increase energy metabolism. Growth Hormone Releasing Peptides, similar to GHRP-6, are most commonly used for treatment of Growth Hormone (GH) deficiencies, eating disorders, obesity, etc. Research has shown that use of these HGH Peptides increases lean muscle mass, strength, stamina and decreases body fat.
Performax Labs AlphaMax – Testosterone Booster – Post Cycle Therapy – Anti Estrogen Testosterone is becoming more and more recognized for its benefits in men of all ages: proper testosterone production is necessary for men who want to live a healthy lifestyle. However, this is not news to the bodybuilding community: we have been looking to increase testosterone for decades.…
GHRP-6 and all GHRP’s are mimetics of ghrelin, a hormone produced by cells of the stomach in response to a fasted condition, including brief fasts. Ghrelin and ghrelin mimetics work by activating the ghrelin receptor, also called the growth hormone secretagogue receptor (GHS-R1a). Elevated ghrelin levels act towards increasing GH levels by stimulation of ghrelin receptors in the pituitary.
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.

Abbreviations: AKT1, RAC-alpha serine/threonine-protein kinase; AMI, acute myocardial infarction; CTGF, connective tissue growth factor; DCM, dilated cardiomyopathy; dP/dt, the rate of left ventricle maximal pressure rise in early systole; DX, doxorubicin; ECM, extracellular matrix; EGF, epidermal growth factor; ERK1/2, extracellular signal-regulated kinase 1/2; GH, growth hormone; GHRH, growth hormone-releasing hormone; GHRPs, growth hormone-releasing peptides; GHS, growth hormone secretagogues; GHS-R, growth hormone secretagogue receptor; GHS-R1a, growth hormone secretagogue receptor type 1a; HIF-1α, hypoxia-inducible factor-1 alpha; I/R, ischemia and reperfusion; IGF-1, insulin-like growth factor-1; IL-1β, interleukin-1 beta; IL-6, interleukin 6; LPS, lipopolysaccharide; LV, left ventricle; LVEF, left ventricular ejection fraction; MBP, mean blood pressure; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; MOD, Multiple Organs Damage; NEP, nitrosylation end products; NIH, National Institute of Health; PDGF, platelet-derived growth factor; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PI-3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PPARγ, peroxisome proliferator-activated receptor gamma; RAS, rennin–angiotensin system; rhGH, recombinant human growth hormone; ROS, reactive oxygen species; TGF-β, transforming growth factor beta; TIMP, tissue inhibitor of metalloproteinase; TNF-α, tumor necrosis factor alpha.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.

At the time that decision was made, paracetamol/caffeine combinations were available over-the-counter in over 50 other countries and had been exempt from scheduling in a number of major markets that are similar to Australia in terms of population type and regulatory status. Experience with the unscheduled sale of this product was extensive: UK 19 years, Ireland 12 years and New Zealand for 7 years. However, the Committee determined not to consider paracetamol combined with caffeine for exemption from scheduling until market experience had been gained with use as a Schedule 2 product in Australia.
In consuming Growth Hormone Releasing Peptide-6 your body is likely to absorb more nitrogen than usual. This in turn facilitates production of protein that can later be used for building muscle mass and burning excess fat in your body. Though it is absolutely safe to consume supplements that are derived from GHRP, the only side effect you may need to deal with is intense hunger that you may experience in as little as half hour of taking the supplement. The silver lining for this drawback is that you can consume lots of foods, especially fruits and vegetables to get the desired results. The contribution made by GHRP 6 towards serving the purpose during workouts is immense.
×